文献速递心力衰竭与心肌病

心力衰竭药物自付费用高:贡献因素与解决方案的最新综述

Contributors and Solutions to High Out-of-Pocket Costs for Heart Failure Medications: A State-of-the-Art Review.
PubMed 文献 · J Am Coll Cardiol · 2025-01-08

该综述以美国医疗体系为例,总结心衰药物自付费用透明化努力的现状。处方药费用影响医疗决策和依从性,但临床决策时个体化费用估算很少可得。缺乏费用透明阻碍成本敏感的共享决策,可导致财务毒性和治疗延迟。美国即将实施的政策变化(如2025年Medicare Part D计划自付药物支出2000美元上限)将影响心衰药物的可及性和可负担性。理解决定药物费用的变量和降低自付费用的资源对全球心衰临床医生至关重要。

要点

  • 心衰药物自付费用影响医疗决策和患者依从性。
  • 临床决策时个体化费用估算很少可得,阻碍成本敏感的共享决策。
  • 2025年Medicare Part D计划将实施2000美元自付药物支出上限。

核心结论

  • 心衰药物自付费用高且缺乏透明,影响决策和依从性,需理解费用变量和降低自付费用的资源。

研究设计与样本

  • 最新综述,以心衰管理指南和美国医疗体系为例总结费用透明化努力现状。

主要发现

  • 处方药费用影响医疗决策和依从性,但临床决策时个体化费用估算很少可得。
  • 缺乏费用透明阻碍成本敏感的共享决策,可导致财务毒性和治疗延迟。
  • 美国即将实施的政策变化将影响心衰药物的可及性和可负担性。

关键数值与推荐

  • 2025年Medicare Part D计划实施2000美元自付药物支出上限。

临床怎么用

  • 心衰临床医生应理解决定药物费用的变量和降低自付费用的资源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As expensive therapeutics rise to the fore of heart failure management, out-of-pocket (OOP) medication costs have become increasingly relevant to patient care. Prescription medication costs influence medical decision-making and affect adherence. Yet, individualized cost estimates are seldom available during clinical encounters when prescription decisions are made. The lack of transparency around medication costs prohibits cost-sensitive shared decision-making and can lead to financial toxicity and delays in therapeutic management. Upcoming policy changes will affect the availability and affordability of heart failure medications in the United States, such as the implementation of a $2,000 cap on OOP drug spending for Medicare Part D Plans in 2025. This state-of-the-art review summarizes the current landscape of cost transparency efforts using heart failure management guidelines and the U.S. health care system as an illustrative example. Understanding the variables involved in determining medication costs and the resources available to reduce OOP cost are paramount for heart failure clinicians and their patients worldwide.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lowe, Gerasta, Balser, et al. Contributors and Solutions to High Out-of-Pocket Costs for Heart Failure Medications: A State-of-the-Art Review. J Am Coll Cardiol. 2025. PMID: 39772358. doi:10.1016/j.jacc.2024.11.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。